Haisco said its self-developed Class 1 innovative intravenous anesthetic, ciprofol injection, has received US FDA approval for induction of general anesthesia in adults. Ciprofol is the first China-originated original intravenous anesthetic to secure international market approval.

May RatingDog China manufacturing PMI 51.8, down 0.4 percentage points from April. Production and demand remain in expansion but momentum slowed; output rose but at a weaker pace. Total new orders continued to expand more slowly; new export orders declined from April into contraction. Cost and price pressures eased: input-material price gains narrowed and output price growth decelerated; firms’ pass‑through moderated. Overall manufacturing expansion slowed but underlying activity remains stable; continued new orders and output support the sector and easing cost pressure helps profit prospects, while weaker external demand is a downside risk.

China's CSI 300 futures (IF) most-active contract fell 0.41%; SSE 50 futures (IH) most-active fell 0.49%; CSI 500 futures (IC) most-active rose 0.27%; CSI 1000 futures (IM) most-active rose 0.42%.